Loading...
•
Dec 31, 2022
Aurinia Q4 2022 Earnings Report
Aurinia reported a 21% increase in total net revenue for Q4 2022, reaching $28.4 million. The company reiterated its net product revenue guidance of $120 to $140 million for fiscal year 2023.
Key Takeaways
Aurinia Pharmaceuticals Inc. reported a total net revenue of $28.4 million for the fourth quarter of 2022, representing a 21% increase compared to the same period in 2021. The company's cash, cash equivalents, and investments totaled $389.4 million as of December 31, 2022. The company reiterated its net product revenue guidance of $120 to $140 million for fiscal year 2023.
Total net revenue for Q4 2022 was $28.4 million, a 21% increase over Q4 2021.
Net product revenue for Q4 2022 was $28.3 million.
Aurinia added 406 PSFs during the fourth quarter 2022, a 15% decrease from the fourth quarter 2021 (477).
Cash, cash equivalents, and investments totaled $389.4 million as of December 31, 2022.
Revenue by Segment
Forward Guidance
For fiscal year 2023, the Company is reiterating its previous net product revenue guidance of $120 to $140 million from sales of LUPKYNIS. This range represents a double-digit percentage increase in net product revenue from sales of LUPKYNIS compared to fiscal year 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...